Inovio Pharmaceuticals (INO)
(Delayed Data from NSDQ)
$11.15 USD
-0.73 (-6.14%)
Updated May 7, 2024 04:00 PM ET
After-Market: $11.13 -0.02 (-0.18%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Brokerage Reports
Inovio Pharmaceuticals, Inc. [INO]
Reports for Purchase
Showing records 241 - 260 ( 363 total )
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Hold Response Submitted; VGX-3100 Phase 3 Trial Starting This Quarter; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2016 Financial Results Reported; VGX-3100 Phase 3 Trial Starting in 1H 2017; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MERS and Zika Vaccines Advance in Phase 1 Trials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Zika Vaccine Produced Robust Immune Response in Phase 1 Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q16 Financial Results; Reiterate Buy and Adjusting Price Target to $13
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 Trial of VGX-3100 Delayed to 1H 2017; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.